Article

Evidence for the Role of Extrapulmonary Vein Substrate in Persistent AF

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating
Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

There is growing evidence for the role of extrapulmonary vein (extra-PV) substrate in AF; that is, atrial fibrosis is a key pathophysiological player in the progress of AF. Prof Hans Kottkamp of Hirslanden Hospital in Zurich, Switzerland, highlighted the research he and his colleagues have been carrying out in this area. Atrial fibrillation does not beget atrial fibrosis, nor is atrial fibrosis related to increased age of the patient.16

Atrial fibrosis is a complex process involving triggers, fibrotic substrate and modulators, and may be caused by multiple potential mechanisms. However, Prof Kottkamp says that it is becoming more and more clear that atrial fibrosis is the pathophysiological key player of the AF substrate, but we simply do not agree where it comes from (see Figure 5). Prof Kottkamp hypothesises that arrhythmia is a manifestation of fibrotic disease and not the other way around, but acknowledges this concept is controversial.

Atrial Fibrosis: The Pathophysiological Key Player of the AF Substrate

Article image

Voltage Mapping and Electrogram Morphology as Surrogates for Atrial Fibrosis

Article image

Voltage mapping and electrogram morphology can be used as surrogates for atrial fibrosis, and used to determine a fibrotic atrial cardiomyopathy (FACM) score: FACM 0 = purple (voltage >1.5 mV), FACM 4 = almost all parts red (voltage <0.5 mV) (see Figure 6).18 The fourth score, dubbed the strawberry, is the most massively and diffusely affected left atrium. “When this is affected, whatever you do, you will not get the patient back to sinus rhythm,” said Prof Kottkamp.

What, then, is to be done with respect to extra-PV substrate in AF? Prof Kottkamp discussed approaches depending on the presentation of the patient. For example, in a patient with persistent AF who has FACM 0, only a PVI is performed. In contrast, for FACM 1, 2 and 3 patients, box isolation of fibrotic areas performed in the first ablation procedure has led to good results.18

Prof Kottkamp has also been working with a new ‘globe’ ablation technology that may help combine stable, multi-electrode contact mapping with ablation in a single tool, and he feels it shows promise with respect to treating atrial fibrosis in the context of AF.

How Can We Explain Recent Trials Indicating No Benefit of Extra-PV Ablation?

Prof Gerhard Hindricks from University of Leipzig began his presentation by describing the different treatment strategies for extra-PV ablation. Durable PVI is the cornerstone of treatment strategies for the clear majority of patients with the various forms and presentations of AF. Add-on strategies that have been evaluated include deployment of linear lesions, complex fractionated atrial electrograms, AF termination, ablation of focal targets and left atrial appendage isolation, rotor detection and ablation, ablation of cardiac ganglia, and ablation of renal nerves. The latter three strategies were not discussed in detail, in favour of the classic moulds of extra-PV ablation.

In reviewing the treatment results, Prof Hindricks focused on several outcome measures, with the primary one being freedom from AF recurrence after ablation. Secondary outcomes parameters include complications, procedural data and resource utilisation. For all treatment strategies, positive effects on the main outcome measure (i.e. reduced AF recurrence rate attributed to the use of the extra-PV ablation strategy) can be found in the literature. However, whenever the treatment strategies had been evaluated in the setting of larger, multicentre studies, structured meta-analyses, or in the few randomised clinical trials available, most add-on strategies have failed to give solid and significant benefits.

After 20 years of AF ablation, no treatment strategy for extra-PV ablation received a recommendation in recent ESC guidelines for catheter ablation of AF, said Prof Hindricks. There is no strong evidence to advocate anything beyond PVI for any subclass of AF population, aside from solid PVI.

When interpreting the current clinical results, it is important to understand some key points and questions:

  • Therapy allocation was mainly based on ECG phenotyping.
  • There was no personalised approach in most studies.
  • Most studies have been too small and underpowered.
  • Most studies were carried out without clearly defined endpoints.
  • Is the effect of additional ablation the same for all patient entities with AF?
  • Did we induce both benefit and harm with a net-to-neutral effect?
  • Did we apply acceptable standardisation of treatment strategies and follow-up?

Outcome after catheter ablation is a complex scenario, and numerous factors play into the risk of recurrence (see Figure 7).

“We have to realise that the technique applied is an important part of the whole set-up that defines the recurrence rate, but it’s just one part among various factors that define the risk of recurrence after catheter ablation of atrial fibrillation,” concluded Prof Hindricks.

Is There an Optimal Extra-PV Substrate Ablation Strategy?

Procedural success for AF is affected by a range of factors – the type of AF, the substrate of the AF, if there is scar tissue, triggers, gender, the presence of valvular disease, left atrial size, and the technique. Dr Amin Al-Ahmad from the Texas Cardiac Arrhythmia Institute in Austin, US, explained that the treatment goal is electrical silence, to eliminate all electrical activity in the posterior wall, as part of the pulmonary vein (PV) ablation strategy.

Isolation is achieved in his practice at about 40 W, and typically with 5–10 g contact force (CF), but the catheter must continuously move and areas must be revisited. This approach to isolating the PV wall has been validated in meta-analyses for both paroxysmal and, even more so, persistent AF patients. Mitigating the risk to the oesophagus can be achieved by using a temperature probe that provides enough coverage of the oesophagus to be accurate,19 or even to move the oesophagus (although researchers are still trying to understand the safety and efficacy of this technique).

However, the question remains as to whether isolating the PV posterior wall is enough. Dr Al-Ahmad presented a case study that showed three of four PVs completely isolated after cryoablation. He asked attendees how they would manage the recurrence, and the audience was split between ablating the PV only, and ablating and looking for triggers.

Outcome After Catheter Ablation – a Complex Scenario

Article image

“If you’re able to provoke arrhythmias, and you target those specific focal triggers, then you do indeed have some benefit in arrhythmia reduction. That’s been our strategy,” said Dr Al-Ahmad. “As we finish our AF ablation, we always look for PV triggers, and we document what they are. Now, if you take them for a third procedure, there are new PV triggers that are occurring – that tells us that this is a progressive disease. It makes sense. You can hit it for a while but ultimately new substrate does appear.”

In addition, pulmonary vein triggers are probably more important earlier in the disease progression and, as the disease progresses, non-PV triggers become more important. Techniques for eliciting them become the biggest challenge, along with how to target them for ablation successfully, efficaciously and safely.

Dr Al-Ahmad said the optimal extra-PV substrate ablation is complete isolation of the PVs, and his group includes the posterior wall of the left atrium. Then they identify triggers using high-dose isoproterenol and, if they can elicit triggers, they completely isolate the trigger substrate.

References

  1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213–20.
    Crossref PubMed
  2. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/ SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterisation, and clinical implication. J Arrhythm 2016;32:247–78.
    Crossref PubMed
  3. Wijesurendra RS, Liu A, Eichhorn C, et al. Lone atrial fibrillation is associated with impaired left ventricular energetics that persists despite successful catheter ablation. Circulation 2016;134:1068–81.
    Crossref PubMed
  4. Kolb C, Nürnbuger S, Ndrepepa G, et al. Modes of initiation of paroxysmal atrial fibrillation from analysis of spontaneously occurring episodes using a 12-lead Holter monitoring system. Am J Cardiol 2001;88:853–7.
    Crossref PubMed
  5. Ehrlich JR, Cha TJ, Zhang L, et al. Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties. J Physiol 2003;551: 801–13.
    Crossref PubMed
  6. de Groot N, van der Does L, Yaksh A, et al. Direct proof of endo-epicardial asynchrony of the atrial wall during atrial fibrillation in humans. Circ Arrhythm Electrophysiol 2016;9:pii: e003648.
    Crossref PubMed
  7. Kirchof P, Benussi S, Koetecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016;50:e1- e88.
    Crossref PubMed
  8. Pison L, La Meir M, van Opstal A, et al. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 2012;60:54–61.
    Crossref PubMed
  9. Dudink E, Essers B, Holvoet W, et al. Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial. Am Heart J 2017;183:49–53.
    Crossref PubMed
  10. Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: Lessons from a 5-year follow-up. Circulation 2010;122:2368–77.
    Crossref PubMed
  11. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation. Circ Arrythm Electrophysiol 2009;2:349–61.
    Crossref PubMed
  12. de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation: clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725–31.
    Crossref PubMed
  13. Weimar T, Schena S, Bailey MS, et al. The Cox-Maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ Arrhythm Electrophysiol 2012;5:8–14.
    Crossref PubMed
  14. Gallagher MM, Camm AJ. Classification of atrial fibrillation. Pacing Clin Electrophysiol 1997;20:1603–5.
    Crossref PubMed
  15. January CT, Wann LS, Alpert JS. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071–104.
    Crossref PubMed
  16. Platonov PG, Mitrofanova LB, Orshanskaya V, et al. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J Am Coll Cardiol 2011;58:2225–32.
    Crossref PubMed
  17. Kottkamp H, Schreiber D. The substrate in “early persistent” atrial fibrillation: arrhythmia induced, risk factor induced, or from a specific fibrotic atrial cardiomyopathy? J Am Coll Cardiol Clin Electrophysiol 2016;2:140–2.
    Crossref
  18. Kottkamp H, Schreiber D, Moser F, Rieger A. Therapeutic approaches to atrial fibrillation ablation targeting atrial fibrosis. J Am Coll Cardiol EP 2017;3:643–53.
    Crossref
  19. Gianni C, Atoui M, Mohanty S, et al. Difference in thermodynamics between two types of esophageal temperature probes: Insights from an experimental study. Heart Rhythm 2016;13:2195–200.
    Crossref PubMed
  20. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014;11:639–54.
    Crossref PubMed
  21. Steinberg BA, Holmes DN, Ezekowitz MD, et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 2013;165:622-9.
    Crossref PubMed
  22. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and metaanalyses. Circ Arrhythm Electrophysiol 2009;2:349-61.
    Crossref PubMed
  23. Medtronic internal estimates
  24. Raatikainen MJ, Arnar DO, Merkely B, et al. Access to and clinical use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2016 Report from the European Heart Rhythm Association. Europace 2016;18(Suppl 3):iii1–iii79.
    Crossref PubMed
  25. Reddy VY, Dukkipati SR, Neuzil P, et al. Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: Results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study. Circulation 2015;132:907–15.
    Crossref PubMed
  26. Kuck KH, Brugada J, Fürnkranz A. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016;374:2235–45.
    Crossref PubMed
  27. Wright M, Harks E, Kolen A, et al. Contact force is a poor marker of tissue compression in the left atrium. Utility of a novel intra-tissue visualization & ablation system to assess tissue depth in real time. Europace 2014;16(Suppl 2):9–4, ii5
  28. Shah DC, Mandar M. Real-time contact force measurement: a key parameter for controlling lesion creation with radiofrequency energy. Circ Arrhythm Electrophysiol 2015;8:713– 21.
    Crossref PubMed
  29. Chun KRJ, Brugada J, Elvan A, et al. The Impact of Cryoballoon Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation on Healthcare Utilization and Costs: An Economic Analysis From the FIRE AND ICE Trial. J Am Heart Assoc 2017;6:pii: e006043.
    Crossref PubMed
  30. Kimura M, Sasaki S, Owada S, et al. Comparison of lesion formation between contact force-guided and non-guided circumferential pulmonary vein isolation: a prospective, randomized study. Heart Rhythm 2014;11:984–91.
    Crossref PubMed
  31. Nakamura K, Naito S, Sasaki T, et al. Randomized comparison of contact force-guided versus conventional circumferential pulmonary vein isolation of atrial fibrillation: prevalence, characteristics, and predictors of electrical reconnections and clinical outcomes. J Interv Card Electrophysiol 2015;44:235– 45.
    Crossref PubMed
  32. Pedrote A, Arana-Rueda E, Arce-León A, et al. Impact of contact force monitoring in acute pulmonary vein isolation using an anatomic approach. A randomized study. Pacing Clin Electrophysiol 2016;39:361–9.
    Crossref PubMed
  33. Reddy VY, Dukkipati SR, Neuzil P, et al. Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study. Circulation 2015;132:907–15.
    Crossref PubMed
  34. Ullah W, McLean A, Tayebjee MH, et al. Randomized trial comparing pulmonary vein isolation using the SmartTouch catheter with or without real-time contact force data. Heart Rhythm 2016;13:1761–7.
    Crossref PubMed
  35. Perna F, Heist EK, Danik SB, et al. Assessment of catheter tip contact force resulting in cardiac perforation in swine atria using force sensing technology. Circ Arrhythm Electrophysiol 2011;4:218–24.
    Crossref PubMed
  36. Quallich SG, Van Heel M, Iaizzo PA. Optimal contact forces to minimize cardiac perforations before, during, and/or after radiofrequency or cryothermal ablations. Heart Rhythm 2015;12:291–6.
    Crossref PubMed
  37. Yokoyama K, Kakagawa H, Shah DC, et al. Novel contact force sensor incorporated in irrigated radiofrequency ablation catheter predicts lesion size and incidence of steam pop and thrombus. Circ Arrhythm Electrophysiol 2008;1:354–62.
    Crossref PubMed
  38. Kuck KH, Reddy VY, Schmidt B, et al. A novel radiofrequency ablation catheter using contact force sensing: Toccata study. Heart Rhythm 2012;9:18–23.
    Crossref PubMed
  39. Natale A, Reddy VY, Monir G, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol 2014;64:647–56.
    Crossref PubMed
  40. Perino A, Fan J, Schmitt S, et al. Cost variation and associated outcomes of catheter ablation for atrial fibrillation. J Am Coll Cardiol 2015;65(10S):A277" target="_blank">PubMed
  41. Ho SY, Sanchez-Quintana D, Cabrera JA, Anderson RH. Anatomy of the left atrium: implications for radiofrequency ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1999;10:1525–33.
    CrossrefPubMed
  42. Nakamura K, Funabashi N, Uehara M, et al. Left atrial wall thickness in paroxysmal atrial fibrillation by multislice-CT is initial marker of structural remodeling and predictor of transition from paroxysmal to chronic form. Int J Cardiol 2011;148:139–47.
    Crossref PubMed
  43. Platonov PG, Ivanov V, Ho SY, Mitrofanova L. Left atrial wall thickness in patients with and without atrial fibrillation. J Cardiovasc Electrophysiol 2008;9:689–92.
    Crossref PubMed
  44. Pan NH, Tsao HM, Chang NC, et al. Aging dilates atrium and pulmonary veins. Chest 2008;133:190–6.
    Crossref PubMed
  45. Whitaker J, Rajani R, Chubb H, et al. The role of myocardial wall thickness in atrial arrhythmogenesis. Europace 2016;18:1758–72.
    Crossref PubMed
  46. Mukherjee RK, Chubb H, Harrison JL, et al. Epicardial electroanatomical mapping and radiofrequency ablation in the swine left ventricle under real time MRI guidance. Heart Rhythm 2017;14(Suppl):S191
  47. Jumrussirikul P, Atiga WL, Lardo AC, et al. Prospective comparison of lesions created using a multipolar microcatheter ablation system with those created using a pullback approach with standard radiofrequency ablation in the canine atrium. Pacing Clin Electrophysiol 2000;23:203–13.
    Crossref PubMed
  48. Avitall B, Helms RW, Koblish JB, et al. The creation of linear contiguous lesions in the atria with an expandable loop catheter. J Am Coll Cardiol 1999;33:972–84.
    Crossref PubMed
  49. van Rensburg H, Willems R, Holemans P, et al. Simultaneous creation and evaluation of linear radiofrequency lesions. J Interv Card Electrophysiol 2002;6: 215–24.
    PubMed
  50. Gepstein L, Hayam G, Shpun S, et al. Atrial linear ablations in pigs. Circulation 1999;100:419–26.
    Crossref PubMed
  51. Schwartzman D, Michele JJ, Trankiem CT, Ren JF. Electrogramguided radiofrequency catheter ablation of atrial tissue comparison with thermometry-guide ablation: comparison with thermometry-guide ablation. J Interventional Cardiac Electrophysiol 2001;5:253–66.
    PubMed
  52. Bortone A, Brault-Noble G, Appetiti A, Marijon E. Elimination of the negative component of the unipolar atrial electrogram as an in vivo marker of transmural lesion creation: acute study in canines. Circ Arrhythm Electrophysiol 2015;8:905–11.
    Crossref PubMed
  53. Zghaib T, Ipek EG, Zahid S, et al. Association of left atrial epicardial adipose tissue with electrogram bipolar voltage and fractionation: Electrophysiologic substrates for atrial fibrillation. Heart Rhythm 2016;13:2333–9.
    Crossref PubMed
  54. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation 2011;124:2264–74.
    Crossref PubMed
  55. Khurram IM, Habibi M, Gucuk IE, et al. Left atrial LGE and arrhythmia recurrence following pulmonary vein isolation for paroxysmal and persistent AF. JACC Cardiovasc Imaging 2016;9:142–8.
    Crossref
  56. Habibi M, Lima JA, Gucuk IE, et al. The association of baseline left atrial structure and function measured with cardiac magnetic resonance and pulmonary vein isolation outcome in patients with drug-refractory atrial fibrillation. Heart Rhythm 2016;13:1037–44.
    Crossref PubMed
  57. Di Biase L, Burkhardt D, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010;121:2550–6.
    Crossref PubMed
  58. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management. Circulation 2014;129:2638–44.
    Crossref PubMed
  59. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017;376:1627–36.
    Crossref PubMed